Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (369)	11/9/1998 8:46:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

The Xerecept trial is not pivotal. If the Phase II is successful, then NTII will be looking for a partner to fund the Phase III. If the Phase II results look anything like the earlier results, then they should have no problem finding a partner. This could be a very significant drug. I know of one analyst that believe that XERECEPT could be worth considerable more to NTI than Memantine and memantine is looking like it could become a major cash cow for the company. The one place that I expect NTI to go from Phase II to an NDA is with the Memantine trial for AIDS Dementia Complex. The Phase II is currently still enrolling patients. However, the latest information indicates that enrollment is almost complete. About 6 mos. after enrollment is complete we should have results. If they are positive, and all the anecdotal evidence suggests that it is, then NTI might well submit an NDA. The safety data that they obtained from MERZ was a critical missing piece for NTI. With that data in hand, they should be able to make a strong case for approval. In addition the political pressure that would be brought to bear to approve an effective, safe treatment for AIDS Dementia Complex could be quite formidable. John de C